Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 37.31
(-0.8%)
USD 37.31
(-0.8%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.45 Billion USD | 8.07% |
| 2022 | 1.34 Billion USD | 15.85% |
| 2021 | 1.16 Billion USD | 55.01% |
| 2020 | 749 Million USD | 5.49% |
| 2019 | 710 Million USD | 24.95% |
| 2018 | 568.21 Million USD | 6.58% |
| 2017 | 533.11 Million USD | 6.49% |
| 2016 | 500.63 Million USD | 25.92% |
| 2015 | 397.57 Million USD | 5.88% |
| 2014 | 375.5 Million USD | 149.78% |
| 2013 | 150.33 Million USD | 4.41% |
| 2012 | 143.99 Million USD | -34.2% |
| 2011 | 218.84 Million USD | 41.73% |
| 2010 | 154.4 Million USD | 1245.24% |
| 2009 | 11.47 Million USD | -93.42% |
| 2008 | 174.5 Million USD | 2.59% |
| 2007 | 170.1 Million USD | 21.21% |
| 2006 | 140.33 Million USD | -5.02% |
| 2005 | 147.75 Million USD | -40.22% |
| 2004 | 247.15 Million USD | 7.52% |
| 2003 | 229.87 Million USD | 0.52% |
| 2002 | 228.69 Million USD | 68.72% |
| 2001 | 135.54 Million USD | 26.84% |
| 2000 | 106.86 Million USD | 17.17% |
| 1999 | 91.2 Million USD | 12.18% |
| 1998 | 81.3 Million USD | 38.27% |
| 1997 | 58.8 Million USD | 125.29% |
| 1996 | 26.1 Million USD | 169.07% |
| 1995 | 9.7 Million USD | -17.09% |
| 1994 | 11.7 Million USD | -14.6% |
| 1993 | 13.7 Million USD | 7.03% |
| 1992 | 12.8 Million USD | 113.33% |
| 1991 | 6 Million USD | 400.0% |
| 1990 | 1.2 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.97 Billion USD | 0.4% |
| 2024 Q1 | 1.96 Billion USD | 35.47% |
| 2023 Q2 | 1.47 Billion USD | 8.3% |
| 2023 FY | 1.45 Billion USD | 8.07% |
| 2023 Q3 | 1.4 Billion USD | -4.75% |
| 2023 Q4 | 1.45 Billion USD | 3.53% |
| 2023 Q1 | 1.36 Billion USD | 1.19% |
| 2022 Q2 | 1.22 Billion USD | 0.09% |
| 2022 FY | 1.34 Billion USD | 15.85% |
| 2022 Q1 | 1.22 Billion USD | 5.27% |
| 2022 Q4 | 1.34 Billion USD | 9.85% |
| 2022 Q3 | 1.22 Billion USD | 0.09% |
| 2021 FY | 1.16 Billion USD | 55.01% |
| 2021 Q1 | 909.78 Million USD | 21.47% |
| 2021 Q4 | 1.16 Billion USD | -9.44% |
| 2021 Q2 | 1.28 Billion USD | 40.75% |
| 2021 Q3 | 1.28 Billion USD | 0.12% |
| 2020 Q4 | 749 Million USD | -6.25% |
| 2020 Q1 | 779.59 Million USD | 9.8% |
| 2020 FY | 749 Million USD | 5.49% |
| 2020 Q2 | 789.18 Million USD | 1.23% |
| 2020 Q3 | 798.93 Million USD | 1.24% |
| 2019 Q2 | 587 Million USD | -7.89% |
| 2019 Q3 | 656.25 Million USD | 11.8% |
| 2019 Q4 | 710 Million USD | 8.19% |
| 2019 FY | 710 Million USD | 24.95% |
| 2019 Q1 | 637.27 Million USD | 12.15% |
| 2018 Q3 | 619 Million USD | 1.45% |
| 2018 Q4 | 568.21 Million USD | -8.21% |
| 2018 FY | 568.21 Million USD | 6.58% |
| 2018 Q1 | 541.63 Million USD | 1.6% |
| 2018 Q2 | 610.13 Million USD | 12.65% |
| 2017 Q2 | 516.53 Million USD | -11.07% |
| 2017 Q3 | 584.49 Million USD | 13.16% |
| 2017 Q4 | 533.11 Million USD | -8.79% |
| 2017 FY | 533.11 Million USD | 6.49% |
| 2017 Q1 | 580.8 Million USD | 16.01% |
| 2016 Q4 | 500.63 Million USD | 4.23% |
| 2016 FY | 500.63 Million USD | 25.92% |
| 2016 Q1 | 395.45 Million USD | -0.53% |
| 2016 Q2 | 473.95 Million USD | 19.85% |
| 2016 Q3 | 480.33 Million USD | 1.34% |
| 2015 Q3 | 463.98 Million USD | 20.1% |
| 2015 Q4 | 397.57 Million USD | -14.31% |
| 2015 Q1 | 452.7 Million USD | 20.56% |
| 2015 FY | 397.57 Million USD | 5.88% |
| 2015 Q2 | 386.31 Million USD | -14.66% |
| 2014 Q3 | 227.05 Million USD | 0.82% |
| 2014 Q2 | 225.2 Million USD | 0.81% |
| 2014 Q1 | 223.4 Million USD | 48.6% |
| 2014 FY | 375.5 Million USD | 149.78% |
| 2014 Q4 | 375.5 Million USD | 65.38% |
| 2013 Q4 | 150.33 Million USD | -31.6% |
| 2013 Q2 | 218 Million USD | 0.81% |
| 2013 Q1 | 216.26 Million USD | 50.19% |
| 2013 FY | 150.33 Million USD | 4.41% |
| 2013 Q3 | 219.8 Million USD | 0.82% |
| 2012 Q1 | 220.3 Million USD | 0.67% |
| 2012 Q3 | 226.46 Million USD | -1.99% |
| 2012 Q4 | 143.99 Million USD | -36.42% |
| 2012 Q2 | 231.05 Million USD | 4.88% |
| 2012 FY | 143.99 Million USD | -34.2% |
| 2011 Q1 | 155.19 Million USD | 0.51% |
| 2011 FY | 218.84 Million USD | 41.73% |
| 2011 Q3 | 212.85 Million USD | 5.76% |
| 2011 Q2 | 201.26 Million USD | 29.68% |
| 2011 Q4 | 218.84 Million USD | 2.81% |
| 2010 Q3 | 145.33 Million USD | -2.89% |
| 2010 Q2 | 149.65 Million USD | 5.68% |
| 2010 Q1 | 141.6 Million USD | 799.21% |
| 2010 FY | 154.4 Million USD | 1245.24% |
| 2010 Q4 | 154.4 Million USD | 6.24% |
| 2009 Q3 | 12.53 Million USD | -90.72% |
| 2009 Q1 | 133.95 Million USD | -23.23% |
| 2009 FY | 11.47 Million USD | -93.42% |
| 2009 Q2 | 135.1 Million USD | 0.85% |
| 2009 Q4 | 15.74 Million USD | 25.66% |
| 2008 Q3 | 167.97 Million USD | -2.1% |
| 2008 Q4 | 174.5 Million USD | 3.88% |
| 2008 FY | 174.5 Million USD | 2.59% |
| 2008 Q1 | 168.36 Million USD | -1.02% |
| 2008 Q2 | 171.58 Million USD | 1.91% |
| 2007 FY | 170.1 Million USD | 21.21% |
| 2007 Q1 | 256.69 Million USD | 82.92% |
| 2007 Q2 | 174.02 Million USD | -32.21% |
| 2007 Q3 | 172.17 Million USD | -1.06% |
| 2007 Q4 | 170.1 Million USD | -1.21% |
| 2006 FY | 140.33 Million USD | -5.02% |
| 2006 Q1 | 145.8 Million USD | -1.32% |
| 2006 Q2 | 143.91 Million USD | -1.3% |
| 2006 Q3 | 142.42 Million USD | -1.04% |
| 2006 Q4 | 140.33 Million USD | -1.46% |
| 2005 Q4 | 147.75 Million USD | -1.6% |
| 2005 Q3 | 150.15 Million USD | -40.77% |
| 2005 Q2 | 253.53 Million USD | 0.2% |
| 2005 Q1 | 253.03 Million USD | 2.38% |
| 2005 FY | 147.75 Million USD | -40.22% |
| 2004 Q4 | 247.15 Million USD | 3.24% |
| 2004 FY | 247.15 Million USD | 7.52% |
| 2004 Q3 | 239.39 Million USD | 2.18% |
| 2004 Q2 | 234.29 Million USD | 1.91% |
| 2004 Q1 | 229.91 Million USD | 0.02% |
| 2003 Q2 | 210.55 Million USD | -4.53% |
| 2003 Q3 | 232.17 Million USD | 10.27% |
| 2003 FY | 229.87 Million USD | 0.52% |
| 2003 Q1 | 220.55 Million USD | -3.56% |
| 2003 Q4 | 229.87 Million USD | -0.99% |
| 2002 Q2 | 201.39 Million USD | 40.38% |
| 2002 Q1 | 143.46 Million USD | 5.84% |
| 2002 FY | 228.69 Million USD | 68.72% |
| 2002 Q4 | 228.69 Million USD | 20.81% |
| 2002 Q3 | 189.3 Million USD | -6.0% |
| 2001 Q1 | 108.85 Million USD | 1.87% |
| 2001 Q4 | 135.54 Million USD | -10.32% |
| 2001 Q3 | 151.14 Million USD | 17.68% |
| 2001 Q2 | 128.43 Million USD | 17.98% |
| 2001 FY | 135.54 Million USD | 26.84% |
| 2000 Q3 | 99.86 Million USD | 1.67% |
| 2000 FY | 106.86 Million USD | 17.17% |
| 2000 Q2 | 98.22 Million USD | 3.33% |
| 2000 Q1 | 95.06 Million USD | 4.24% |
| 2000 Q4 | 106.86 Million USD | 7.0% |
| 1999 Q1 | 82.5 Million USD | 1.48% |
| 1999 Q4 | 91.2 Million USD | 1.56% |
| 1999 FY | 91.2 Million USD | 12.18% |
| 1999 Q3 | 89.8 Million USD | 4.54% |
| 1999 Q2 | 85.9 Million USD | 4.12% |
| 1998 FY | 81.3 Million USD | 38.27% |
| 1998 Q4 | 81.3 Million USD | 6.83% |
| 1998 Q3 | 76.1 Million USD | 2.7% |
| 1998 Q2 | 74.1 Million USD | 25.81% |
| 1998 Q1 | 58.9 Million USD | 0.17% |
| 1997 Q3 | 35.6 Million USD | 1.42% |
| 1997 FY | 58.8 Million USD | 125.29% |
| 1997 Q1 | 25.8 Million USD | -1.15% |
| 1997 Q4 | 58.8 Million USD | 65.17% |
| 1997 Q2 | 35.1 Million USD | 36.05% |
| 1996 FY | 26.1 Million USD | 169.07% |
| 1996 Q4 | 26.1 Million USD | 158.42% |
| 1996 Q1 | 10.4 Million USD | 7.22% |
| 1996 Q2 | 9.9 Million USD | -4.81% |
| 1996 Q3 | 10.1 Million USD | 2.02% |
| 1995 Q3 | 9.9 Million USD | -4.81% |
| 1995 Q1 | 11 Million USD | -5.98% |
| 1995 Q4 | 9.7 Million USD | -2.02% |
| 1995 FY | 9.7 Million USD | -17.09% |
| 1995 Q2 | 10.4 Million USD | -5.45% |
| 1994 FY | 11.7 Million USD | -14.6% |
| 1994 Q1 | 12.9 Million USD | -5.84% |
| 1994 Q3 | 12.2 Million USD | 0.83% |
| 1994 Q4 | 11.7 Million USD | -4.1% |
| 1994 Q2 | 12.1 Million USD | -6.2% |
| 1993 FY | 13.7 Million USD | 7.03% |
| 1993 Q1 | 8.9 Million USD | -30.47% |
| 1993 Q2 | 9.7 Million USD | 8.99% |
| 1993 Q3 | 11.1 Million USD | 14.43% |
| 1993 Q4 | 13.7 Million USD | 23.42% |
| 1992 FY | 12.8 Million USD | 113.33% |
| 1992 Q4 | 12.8 Million USD | -3.03% |
| 1992 Q1 | 10.7 Million USD | 78.33% |
| 1992 Q2 | 12.2 Million USD | 14.02% |
| 1992 Q3 | 13.2 Million USD | 8.2% |
| 1991 Q1 | 1.4 Million USD | 16.67% |
| 1991 Q4 | 6 Million USD | -7.69% |
| 1991 FY | 6 Million USD | 400.0% |
| 1991 Q3 | 6.5 Million USD | 6.56% |
| 1991 Q2 | 6.1 Million USD | 335.71% |
| 1990 Q4 | 1.2 Million USD | 0.0% |
| 1990 FY | 1.2 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dynavax Technologies Corporation | 256.91 Million USD | -465.769% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 84.786% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -3400.226% |
| Perrigo Company plc | 4.07 Billion USD | 64.316% |
| Illumina, Inc. | 2.26 Billion USD | 35.741% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 95.837% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -145253.9% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 89.786% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -736.555% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -5285.472% |
| Waters Corporation | 2.35 Billion USD | 38.292% |
| Biogen Inc. | 7.33 Billion USD | 80.192% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -3714.663% |
| Evolus, Inc. | 126.54 Million USD | -1048.625% |
| Adicet Bio, Inc. | 17.7 Million USD | -8110.693% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -168.703% |
| FibroGen, Inc. | 170.45 Million USD | -752.741% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 46.854% |
| Homology Medicines, Inc. | 44.05 Million USD | -3199.448% |
| Geron Corporation | 85.89 Million USD | -1592.149% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 39.386% |
| Editas Medicine, Inc. | 36.53 Million USD | -3878.375% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 46.223% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -226.595% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -3267.246% |
| bluebird bio, Inc. | 330.32 Million USD | -340.032% |
| Myriad Genetics, Inc. | 145 Million USD | -902.441% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -6859.983% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -28.192% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -115260.238% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -1160.156% |
| Zoetis Inc. | 6.8 Billion USD | 78.634% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -32919.968% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 32.948% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -2411.645% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -79.804% |
| Nektar Therapeutics | 230.4 Million USD | -530.874% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -679.913% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -47184.938% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -3901.704% |
| Verastem, Inc. | 41.55 Million USD | -3397.7% |
| OPKO Health, Inc. | 326.56 Million USD | -345.101% |
| Exelixis, Inc. | 189.94 Million USD | -665.246% |
| Imunon, Inc. | 1.13 Million USD | -127482.545% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -4.061% |
| uniQure N.V. | 138.4 Million USD | -950.177% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -239.295% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -962508.609% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 3.049% |
| Blueprint Medicines Corporation | 774.12 Million USD | -87.766% |
| Insmed Incorporated | 1.2 Billion USD | -20.726% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -2450.605% |
| TG Therapeutics, Inc. | 110.79 Million USD | -1211.918% |
| Incyte Corporation | 38.28 Million USD | -3696.43% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -65.645% |